clarus_final_indentity.jpg
Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction
18 août 2022 16h05 HE | Clarus Therapeutics Holdings, Inc.
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year ...
clarus_final_indentity.jpg
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
09 juin 2022 09h05 HE | Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
18 mai 2022 09h05 HE | Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent...
clarus_final_indentity.jpg
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
16 mai 2022 16h05 HE | Clarus Therapeutics Holdings, Inc.
First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year ...
clarus_final_indentity.jpg
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
12 mai 2022 09h05 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
10 mai 2022 09h05 HE | Clarus Therapeutics Holdings, Inc.
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of...
clarus_final_indentity.jpg
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
09 mai 2022 09h05 HE | Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 ...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
28 avr. 2022 09h05 HE | Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
27 avr. 2022 13h43 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
25 avr. 2022 09h20 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...